Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes |
Apr 2024 |
Journal of Internal Medicine |
Myelodysplastic Syndromes (MDS) |
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs |
Dec 2020 |
Journal of Managed care and specialty pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
Aug 2020 |
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
May 2024 |
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
Jan 2024 |
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
Jun 2023 |
Lancet |
Myelodysplastic Syndromes (MDS) |